The Changing Policy and Communications Environment and Implications for Pharma Marketing, Part 3

Here is the last of the 3-part series about the impact of expected upcoming changes in the policy environment and the tremendous migration in the communications environment and  how this affects the marketing of pharmaceutical products.  In this last installment, there is an examination of just a few of the many possibilities that are open to pharmaceutical involvement to migrate marketing into digital in anticipation of these expected challenges to traditional means of marketing, as Congress seeks to reign in DTC and monitor and even curtail the relationships that industry has with physicians and patients.